Luc-Actes: une unité à construire

(Résumé de l'ouvrage) This volume contains the papers presented at the 47th Colloquium Biblicum Lovaniense (Leuven, 1998). The general theme of the meeting was the unity of the Gospel of Luke and the Acts of the Apostles. Main papers on this topic were read by R.L. Brawley, J. Delobel, A. Denaux, J.A. Fitzmeyer, F.W. Horn, J. Kremer, A. Lindemann, O. Mainville, D. Marguerat, F. Neirynck, W. Radl, M. Rese, J. Taylor, C.M. Tuckett, and J. Verheyden. While a large majority of scholars agree that Luke intended his work to cover both the past and the continuing history of Jesus (Gospel and Acts), the essays also illustrate the complexities of this view on the unity of Luke-Acts when it comes to interpret the various aspects of Lukan theology, christology, pneumatology, and ecclesiology, the expansion of the Church in light of its Jewish origins, the genre of Luke-Acts, and the literary and stylistic means Luke used to make his work a unity. In total the volume includes some 40 papers, of which 24 are offered papers: L. Alexander, H. Baarlink, M. Bachmann, D. Bechard, T.L. Brodie, G.P. Carras, A. del Agua, C. Focant, G. Geiger, B.J. Koet, V. Koperski, D.P. Moessner, G. Oegema, J. Pichler, E. Plümacher, A. Puig i Tarrèch, U. Schmid, B. Schwank, N. Taylor, P.J. Tomson, S. Van den Eynde, S. Walton, G. Wasserberg, F. Wilk. This collection is an invaluable contribution to current discussions in Lukan study and to a nuanced understanding of the relationship between Luke's two volumes.

The new direct oral anticoagulants in special indications: rationale and preliminary data in cancer, mechanical heart valves, anti-phospholipid syndrome, and heparin-induced thrombocytopenia and beyond.

The present review will briefly summarize the interplay between coagulation and inflammation, highlighting possible effects of direct inhibition of factor Xa and thrombin beyond anticoagulation. Additionally, the rationale for the use of the new direct oral anticoagulants (DOACs) for indications such as cancer-associated venous thromboembolism (CAT), mechanical heart valves, thrombotic anti-phospholipid syndrome (APS), and heparin-induced thrombocytopenia (HIT) will be explored. Published data on patients with cancer or mechanical heart valves treated with DOAC will be discussed, as well as planned studies in APS and HIT. Although at the present time published evidence is insufficient for recommending DOAC in the above-mentioned indications, there are good arguments in favor of clinical trials investigating their efficacy in these contexts. Direct inhibition of factor Xa or thrombin may reveal interesting effects beyond anticoagulation as well.

Prospective evaluation of three point of care devices for glycemia measurement in a neonatal intensive care unit.

Hypoglycemia, if recurrent, may have severe consequences on cognitive and psychomotor development of neonates. Therefore, screening for hypoglycemia is a daily routine in every facility taking care of newborn infants. Point-of-care-testing (POCT) devices are interesting for neonatal use, as their handling is easy, measurements can be performed at bedside, demanded blood volume is small and results are readily available. However, such whole blood measurements are challenged by a wide variation of hematocrit in neonates and a spectrum of normal glucose concentration at the lower end of the test range. We conducted a prospective trial to check precision and accuracy of the best suitable POCT device for neonatal use from three leading companies in Europe. Of the three devices tested (Precision Xceed, Abbott; Elite XL, Bayer; Aviva Nano, Roche), Aviva Nano exhibited the best precision. None completely fulfilled the ISO-accuracy-criteria 15197: 2003 or 2011. Aviva Nano fulfilled these criteria in 92% of cases while the others were <87%. Precision Xceed reached the 95% limit of the 2003 ISO-criteria for values ≤4.2 mmol/L, but not for the higher range (71%). Although validated for adults, new POCT devices need to be specifically evaluated on newborn infants before adopting their routine use in neonatology.

MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T.

Recently, the spin-echo full-intensity acquired localized (SPECIAL) spectroscopy technique was proposed to unite the advantages of short TEs on the order of milliseconds (ms) with full sensitivity and applied to in vivo rat brain. In the present study, SPECIAL was adapted and optimized for use on a clinical platform at 3T and 7T by combining interleaved water suppression (WS) and outer volume saturation (OVS), optimized sequence timing, and improved shimming using FASTMAP. High-quality single voxel spectra of human brain were acquired at TEs below or equal to 6 ms on a clinical 3T and 7T system for six volunteers. Narrow linewidths (6.6 +/- 0.6 Hz at 3T and 12.1 +/- 1.0 Hz at 7T for water) and the high signal-to-noise ratio (SNR) of the artifact-free spectra enabled the quantification of a neurochemical profile consisting of 18 metabolites with Cramér-Rao lower bounds (CRLBs) below 20% at both field strengths. The enhanced sensitivity and increased spectral resolution at 7T compared to 3T allowed a two-fold reduction in scan time, an increased precision of quantification for 12 metabolites, and the additional quantification of lactate with CRLB below 20%. Improved sensitivity at 7T was also demonstrated by a 1.7-fold increase in average SNR (= peak height/root mean square [RMS]-of-noise) per unit-time.